A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients

Inclusion Criteria: * Subjects with Type 2 Diabetes Mellitus * 20\~69 years old * BMI \< 30kg/m2 * HbA1c between 7% and 11% * receiving no oral antihyperglycemic agent for more than seven days for at least 8 weeks * Willing to adhere to protocol requirements and sign a informed consent form Exclusion Criteria: * Subjects with Type 1 Diabetes Mellitus * FPG \> 270mg/dL * Subjects having insulin treatment * Subjects with acute or chornic metaboic acidosis * Subjects with cardiovascular disease * Subjects with chronic GI disease * Subjects with a history of substance or alchol abuse within 1 year * Subjects with a history of hypersensitivity to biguanide or a-GI * Subjects with hypopituitarism or hypocorticalism * Subjects with cancer * Subjects who take corticosteriods or plan to take corticosteroid * AST and ALT \> 2.5 times the upper limit of normal * Creatinine level \> 1.5mg/dL in male and 1.4mg/dL in female * SBP \> 150mmHg or DBP \> 90mmHg * Subjects who work the night shift * Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control * Subjects who have participated in other study within 3 months * Subjects judged to be unsuitable for this trial by investigator